Webinar: LEAN MASLD: Diagnosis, Natural History, and Treatment in 2026

Date : Tuesday, October 27, 12:00 pm - 1:00 pm (EDT)

Moderators:  Robert Fontana, MD, FAASLD and Pinelopi Manousou  
Presenters:  Scott Isaacs, MD; Basile Njei, MD, PhD; Vincent Chen, MD, MS; and Arun Sanyal, MD, FAASLD

This webinar is designed to identify newly proposed definitions of obesity and the proposed nomenclature for MASLD/METALD and ALD. Faculty will describe the epidemiological studies of cross sectional and longitudinal cohorts of lean MASLD patients, and the associated risk of MALO and CV outcomes compared to controls. Lastly, they will describe genetic and metabolic factors in the pathogenesis of lean MASLD and identify the current FDA approved therapies for non-cirrhotic MASLD in patients who are lean or underweight.

Learning Objectives: 
Upon completion of this activity, participants will be able to: 
     - Identify newly proposed definitions of obesity and the proposed nomenclature for MASLD/METALD and ALD 
     - Describe the epidemiological studies of cross sectional and longitudinal cohorts of lean MASLD patients and the associated risk of MALO and CV outcomes 
     - Describe genetic and metabolic factors in the pathogenesis of lean MASLD 
     - Identify the current FDA approved therapies for non-cirrhotic MASLD in patients who are lean and underweight 

This activity offers AMA PRA Category 1 Credits™